Navigation Links
K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus
Date:6/17/2011

e" of the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2011 ("2011 Form 10-K");

(10) the two agreements between the Company and the Office of Inspector General of the U.S. Department of Health and Human Services ("HHS OIG") pertaining to the exclusion of our former chief executive officer from participation in federal healthcare programs and pertaining to the dissolution of our ETHEX subsidiary, in order to resolve the risk of potential exclusion of our Company, as more fully described in Part I, Item 1—"Business—(b)Significant Developments—Agreements with HHS OIG" of the Company's 2011 Form 10-K;

(11) the plea agreement between the Company and the U.S. Department of Justice and the Company's obligations therewith, as well as the related material adverse effect, if any, on its revenue, assets and liquidity and capital resources, as more fully described in Note 1—"Description of Business—Plea Agreement with the U.S. Department of Justice" of  the Notes to the Consolidated Financial Statements included in the  Company's 2011 Form 10-K;

(12) changes in the current and future business environment, including interest rates and capital and consumer spending;

(13) the availability of raw materials and/or products, including Makena™ and Evamist®, manufactured for the Company under contract manufacturing agreements with third parties;

(14) the regulatory environment, including legislative, governmental or regulatory agency and judicial actions and changes in applicable laws or regulations, including the risk of obtaining necessary state licenses in a timely manner;

(15) fluctuations in revenues;

(16) the difficulty of predicting the pattern of inventory movements by the Company's customers;

(17) risks that the Company may not ultimately prevail in litigation, including product liabili
'/>"/>

SOURCE K-V Pharmaceutical Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Par Pharmaceutical Reports Second Quarter 2008 Results
3. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
4. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
5. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
6. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
7. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
8. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
9. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
10. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
11. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... 2015  Neuralstem, Inc. (NYSE MKT: CUR), a biopharmaceutical ... molecule and cell therapy treatments for central nervous system ... listing on the NASDAQ Capital Market under the symbol ... on the NYSE MKT until the market close on ... is expected to commence on July 13, 2015. ...
(Date:6/29/2015)... ... June 29, 2015 , ... The StampedeCon 2015 ... for the fourth year in a row, will bring top technology professionals to St. ... at the intersection of data and technology. The event is proudly sponsored by DataStax, ...
(Date:6/29/2015)... NEW YORK , June 29, 2015   For ... of life sciences to assess their overall digital maturity ... to show that these companies are not maturing fast ... the healthcare industry in numerous ways overall and customers ... industries in terms of digital customer engagement.  ...
(Date:6/26/2015)... , June 26, 2015  SeraCare Life Sciences, ... manufacturers, today announced that it has signed a ... National Cancer Institute (NCI), part of the National ... positive controls for cancer assays.  The CRADA will ... accurately quantitate control DNA biosynthetics spiked into a ...
Breaking Biology Technology:Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 2Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 3StampedeCon Announces 2015 Agenda 2StampedeCon Announces 2015 Agenda 3Results from Digital Maturity Study Show Pharma Lagging 2Results from Digital Maturity Study Show Pharma Lagging 3Results from Digital Maturity Study Show Pharma Lagging 4SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 2SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 3
... BOSTON, March 12 Vical Incorporated (Nasdaq:,VICL) announced ... of its,product development programs on Monday, March 17, ... Conference (Boston -- March 17-20)., About Vical, ... on its,patented DNA delivery technologies for the prevention ...
... 11:00 a.m. ET; 8:00 a.m. PT, VANCOUVER and ... OTC: MGIFF), a clinical-stage developer of drugs for infectious,diseases, ... March 13,2008 at 11:00 a.m. ET (8:00 a.m. PT) ... January 31, 2008 and provide an update on,company activities. ...
... (Nasdaq: IDEV ) today announced the Company will ... Care Conference, on,Tuesday, March 18, 2008 at 1:40 pm ... presentation will be web cast live and may be,accessed ... at, http://www.indevus.com ., About Indevus, Indevus Pharmaceuticals, ...
Cached Biology Technology:Vical to Present at Cowen and Company Health Care Conference 2Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference 2Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference 3
(Date:6/17/2015)... HILDEN , Deutschland und GERMANTOWN, Maryland ... Investigator ®   Produktlinie mit ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ... neue STR-Testkits der Produktlinie Investigator ... DNA-Spuren in den Markt eingeführt. Die neuen Kits zur ...
(Date:6/16/2015)... /CNW Telbec/ - handyem Inc. and FlowMetric Diagnostics ... of handyem,s HPC-150 portable flow cytometer within FlowMetric ... unprecedented model of mobile laboratory platform is presented ... Pennsylvania Convention Center, ... to 18 th 2015.  By virtue of ...
(Date:6/15/2015)... -- According to a new market research ... and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image ... The Natural Language Processing Market is expected to grow ... the forecast period 2015-2020. Browse 65 ... spread   through 155 P ages and in-depth ...
Breaking Biology News(10 mins):QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5
... protein that regulates gene expression may play a role in ... psychiatric disease. As reported in the latest issue of ... Bipolar Disorders, levels of SP4 (specificity protein 4) were lower ... from patients with bipolar disorder. The study suggests that normalization ...
... DST Health Solutions , LLC, today announced ... (CCHP) has implemented its PowerMHC® core claims administration platform ... new market requirements and enhance data integration. In addition, ... line service for CCHP, which supports more than 31,000 ...
... of a cellular mechanism linked to the toxicity of ... study, published in Environmental Science & Technology , ... neurological diseases such as Alzheimer,s. "I,m not implying ... Michael Plewa, lead scientist and professor of genetics in ...
Cached Biology News:Gene regulatory protein is reduced in bipolar disorder 2Gene regulatory protein is reduced in bipolar disorder 3DST Health Solutions' Integrated Care Management Suite Improves Care Quality, Population Management of 31,000+ Member Health Plan 2DST Health Solutions' Integrated Care Management Suite Improves Care Quality, Population Management of 31,000+ Member Health Plan 3Research links water disinfection byproducts to adverse health effects 2Research links water disinfection byproducts to adverse health effects 3
Mynox is intended for research use only. Mynox is used for the elimination of Mycoplasma and Acholeplasma in cell and virus cultures, and other biologicals....
Convenient 10X buffer concentrate used to maximize binding to the solid phase in microwell ELISA. Formulated to provide optimal pH and ionic strength for binding of antibodies and some antigens. Co...
... can be used to label ... covalently bound acridinium NHS ester ... presence of hydrogen peroxide. Acridinium ... used as a detection method ...
A trigger solution for Flashlight labeled materials....
Biology Products: